J&J's growth strategy following the Kenvue separation is concentrated on two strategic imperatives: maintaining and growing pharmaceutical franchise leadership in oncology and immunology while building the next wave of MedTech revenue through surgical robotics, electrophysiology, and digital surgery platforms. The oncology growth strategy centers on expanding Darzalex's addressable market through new indications, new combination regimens, and subcutaneous formulations that improve patient convenience and compliance. Darzalex's expansion from relapsed/refractory multiple myeloma into frontline therapy, and into smoldering myeloma prevention, has progressively expanded the addressable patient population for each regulatory approval. The CAR-T therapy Carvykti, initially approved for heavily pre-treated myeloma, is pursuing earlier-line indications that dramatically expand its potential commercial scale. Immunology pipeline development focuses on building beyond the IL-23 selectivity advantage of Tremfya into next-generation mechanisms including TYK2 inhibition, IL-19 inhibition, and antibody-drug conjugate approaches for inflammatory diseases. The immunology market — encompassing inflammatory bowel disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, and emerging indications — continues to expand as biologics replace older therapies and new mechanisms address patients who do not respond to existing options. The MedTech surgical platform strategy is J&J's largest capital commitment outside of pharmaceutical R&D. The Ottava surgical robotics platform, the Monarch bronchoscopy robot (acquired through Auris Health), and the Velys robotic knee replacement system represent a multi-procedure robotics strategy designed to capture share across soft tissue, pulmonary, and orthopedic surgery as robotics penetration grows from current low single-digit percentages of eligible procedures toward majority adoption over the next decade.